Aripiprazole-induced parkinsonism

International Clinical Psychopharmacology

Volumn 21, Issue 2, 2006, Pages 127-129

  Sharma, Ashish ^a,b   Sorrell, James H ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Aripiprazole; EPS; Parkinsonism

Indexed keywords

ARIPIPRAZOLE; CETIRIZINE; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; DOPAMINE SEROTONIN SYSTEM STABILIZER; FLUTICASONE PROPIONATE; LISINOPRIL; SEROTONIN AGONIST; UNCLASSIFIED DRUG; VALPROATE SEMISODIUM; VENLAFAXINE; NEUROLEPTIC AGENT; PIPERAZINE DERIVATIVE; QUINOLONE DERIVATIVE;

ADULT; ANHEDONIA; ARTICLE; CASE REPORT; CLINICAL FEATURE; DEPRESSION; DRUG INDUCED DISEASE; EXTRAPYRAMIDAL SYMPTOM; EYELID REFLEX; FEMALE; FOLLOW UP; HUMAN; IRRITABILITY; PARKINSONISM; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RESTLESSNESS; RISK FACTOR; SLEEP DISORDER; SYMPTOM; CHEMICALLY INDUCED DISORDER; MAJOR DEPRESSION; MALE; MIDDLE AGED;

ANTIPSYCHOTIC AGENTS; DEPRESSIVE DISORDER, MAJOR; HUMANS; MALE; MIDDLE AGED; PARKINSONIAN DISORDERS; PIPERAZINES; QUINOLONES;

EID: 33645223714     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.yic.0000185025.40656.30     Document Type: Article

References (11)

1. Burris KD, Molski TF, Xu C, Ryan E, Tottori K, Kikuchi T, et al. (2002). Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther 302:381-389.
2. Kane JM, Carson WH, Saha AR, McQuade RD, Ingenito GG, Zimbroff DL, Ali MW (2002). Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry 63:763-771.
3. Kapur S, Seeman P (2001). Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics? A new hypothesis. Am J Psychiatry 158:360-369.
4. Lieberman JA. Aripiprazole. In: Schatzberg AF, Nemeroff CB, editors. The American psychiatric publishing textbook of psychopharmacology, 3rd edn. Washington, DC: American Psychiatric Association; 2000, pp. 487-494.
5. Lieberman JA (2004). Dopamine partial agonists: a new class of antipsychotic. CNS Drugs 18:251-267.
6. Lieberman JA, Mailman RB, Duncan G, Sikich L, Chakos M, Nichols DE, Kraus JE (1998). Serotonergic basis of antipsychotic drug effects in schizophrenia. Biol Psychiatry 44:1099-1117.
7. McGavin JK, Goa KL (2002). Aripiprazole. CNS Drugs 16:779-786.
8. Miller CH, Fleischhacker WW (2000). Managing antipsychotic-induced acute and chronic akathisia. Drug Saf 22:73-81.
9. Pierre JM (2005). Extrapyramidal symptoms with atypical antipsychotics: incidence, prevention and management. Drug Saf 28:191-208.
10. Remington G, Kapur S (1999). D2 and 5-HT2 receptor effects of antipsychotics: bridging basic and clinical findings using PET. J Clin Psychiatry 60 (Suppl 10):15-19.
11. Wirshing WC (2001). Movement disorders associated with neuroleptic treatment. J Clin Psychiatry 62 (Suppl 21):15-18.